Eliquis Patent Expiry Highlights a Moving Pharmacy Market

Market Signal

Eliquis, one of the world's most widely used blood thinners, is approaching a significant transition in its product lifecycle as patent protections give way to generic competition.

The underlying U.S. composition patent for apixaban, the active ingredient in Eliquis, expires in November 2026. However, patent litigation and settlements have allowed Bristol Myers Squibb and Pfizer to preserve U.S. market exclusivity longer, with certain generic manufacturers permitted to launch beginning in April 2028.

The eventual introduction of lower-cost generic alternatives could materially reduce pharmacy spending for employers with members taking the drug.

But the more important story may be what happens around that transition.

Pharmaceutical pricing rarely moves from Point A to Point B in a single step. Patent expirations, exclusivity periods, generic launches, additional competitors, formulary changes and manufacturer lifecycle strategies can create a sequence of pricing and access changes over a relatively short period.

For an employer health plan, yesterday's best purchasing strategy may no longer be tomorrow's.

Why This Matters

Eliquis provides a useful example because a member taking the medication can represent thousands of dollars in annual pharmacy spend.

But the same market dynamics exist much further up the cost spectrum.

A specialty medication costing $60,000 or $160,000 annually can experience changes in patent protection, biosimilar competition, manufacturer assistance, distribution channels, formulary positioning or alternative sourcing opportunities.

Each event can materially change the fair-market price available for that medication.

This creates an important distinction between having access to a discount and having a health plan capable of continuously identifying the best available purchasing channel.

A contract negotiated at the beginning of the year may have been competitive when it was signed. Six months later, the market surrounding a high-cost medication could look entirely different.

At scale, failing to respond to those changes can leave significant dollars trapped inside an outdated purchasing arrangement.

HPX Perspective

At HPX, we believe prescription drug purchasing requires dynamic and proactive plan administration.

The objective should not simply be to negotiate a better pharmacy contract once every few years. It should be to continuously source medications at fair-market value as the underlying marketplace changes.

That becomes difficult when the health plan is built around a single entity controlling the PBM, formulary, pharmacy network, contracting structure and sourcing channels.

No single purchasing channel can reasonably be expected to represent the best available economics for every medication at every point in time.

Instead, employers should have the contractual flexibility and administrative infrastructure to respond when a new generic becomes available, a biosimilar enters the market, manufacturer economics change, or another legitimate sourcing channel produces materially better value.

Eliquis may represent roughly $6,000 of annual spend for an individual member. The exact same structural issue can apply to a specialty therapy costing ten or twenty times as much.

The stakes rise quickly.

Looking Ahead

The pharmaceutical marketplace will only become more dynamic as major drugs lose exclusivity and manufacturers respond with new formulations, indications and product strategies.

For employers, that makes flexibility increasingly valuable.

The question is no longer simply whether the health plan negotiated a competitive pharmacy arrangement at renewal.

The better question is:

When the market changes tomorrow, how quickly can our health plan change with it?

A modern health plan should be designed to continuously evaluate the market, identify meaningful changes in pricing and access, and act when better economics become available.

Because in a market that can change several times within a year, a static purchasing model can become expensive very quickly.